Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk’s blockbuster diabetes and weight-loss drug Ozempic, Hypera’s chief executive said on Friday. https://t.co/JuroIvjI6x pic.twitter.com/2IWxGWrhfh
— Reuters (@Reuters) March 22, 2025
The post Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk’s blockbuster diabetes and weight-loss drug Ozempic, Hypera’s chief executive said on Friday. reuters.com/business/healt… first appeared on The News And Times Review – NewsAndTimes.org.
